Changeflow GovPing Healthcare & Life Sciences USAN Council Adopts TAM Nonproprietary Name
Routine Notice Added Final

USAN Council Adopts TAM Nonproprietary Name

Email

Summary

The USAN Council, operating in cooperation with the FDA, has adopted the nonproprietary name 'TAM' for a substance. The adopted name has been filed with the FDA as a public notice. This naming action establishes the official United States Adopted Name for the substance, which will serve as its standard nonproprietary designation in pharmaceutical and medical contexts.

Published by FDA on regulations.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USAN Council has officially adopted the nonproprietary name 'TAM' for a substance, with the adoption filed and documented through the FDA's regulatory docket system. This is a routine nomenclature action establishing the standardized US Adopted Name.

Affected parties in the pharmaceutical and healthcare sectors should note the newly adopted name for compliance with labeling, prescribing, and regulatory documentation requirements where nonproprietary names are specified.

Archived snapshot

Apr 22, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Content

Download File

Download

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
FDA-2026-P-4112-0035

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug naming Regulatory filings
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!